Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma

BACKGROUND: Plasminogen activator inhibitor 1 (PAI-1) was previously established to impact several phenotypes in many kinds of cancer, including pancreatic cancer. However, its prognostic significance in pancreatic ductal adenocarcinoma (PDAC) needs support of further evidence. This study was design...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wen-Jing, Zhou, Li, Liang, Zhi-Yong, Zhou, Wei-Xun, You, Lei, Zhang, Tai-Ping, Zhao, Yu-Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302640/
https://www.ncbi.nlm.nih.gov/pubmed/30539907
http://dx.doi.org/10.4103/0366-6999.247211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302640/
https://www.ncbi.nlm.nih.gov/pubmed/30539907
http://dx.doi.org/10.4103/0366-6999.247211

Ejemplares similares